Predicting Infection Risk in Multiple Sclerosis Patients Treated with Ocrelizumab: A Retrospective Cohort Study-Reference-Cited by-同舟云学术

Predicting Infection Risk in Multiple Sclerosis Patients Treated with Ocrelizumab: A Retrospective Cohort Study

Published:2021-04-13 Issue:8 Volume:35 Page:907-918
ISSN:1172-7047
Container-title:CNS Drugs
language:en
Short-container-title:CNS Drugs

Author:

Seery Nabil,Sharmin Sifat,Li Vivien,Nguyen Ai-Lan,Meaton Claire,Atvars Roberts,Taylor Nicola,Tunnell Kelsey,Carey John,Marriott Mark P.,Buzzard Katherine A.,Roos Izanne,Dwyer Chris,Baker Josephine,Taylor Lisa,Spriggs Kymble,Kilpatrick Trevor J.,Kalincik Tomas,Monif Mastura

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Psychiatry and Mental health,Neurology (clinical)

Link

https://link.springer.com/content/pdf/10.1007/s40263-021-00810-3.pdf

Reference58 articles.

1. Harding K, Williams O, Willis M, Hrastelj J, Rimmer A, Joseph F, et al. Clinical outcomes of escalation vs early intensive disease-modifying therapy in patients with multiple sclerosis. JAMA Neurol. 2019;76(5):536–41.

2. Buron MD, Chalmer TA, Sellebjerg F, Barzinji I, Christensen JR, Christensen MK, et al. Initial high-efficacy disease-modifying therapy in multiple sclerosis: a nationwide cohort study. Neurology. 2020;95(8):e1041–51.

3. Brown JWL, Coles A, Horakova D, Havrdova E, Izquierdo G, Prat A, et al. Association of initial disease-modifying therapy with later conversion to secondary progressive multiple sclerosis. JAMA. 2019;321(2):175–87.

4. Persson R, Lee S, Ulcickas YM, Wagner UMCM, Minton N, Niemcryk S, et al. Infections in patients diagnosed with multiple sclerosis: a multi-database study. Mult Scler Relat Disord. 2020;41:101982.

5. Wijnands JM, Kingwell E, Zhu F, Zhao Y, Fisk JD, Evans C, et al. Infection-related health care utilization among people with and without multiple sclerosis. Mult Scler. 2017;23(11):1506–16.

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Ocrelizumab in people with primary progressive multiple sclerosis: A real-world multicentric study;Multiple Sclerosis and Related Disorders;2024-09

2. Parenteral anti-B cell therapy for multiple sclerosis: From origins to the creation of the Russian drug divosilimab;Meditsinskiy sovet = Medical Council;2024-08-15

3. Ocrelizumab in MS patients with persistence of disease activity after alemtuzumab: A multi-center Italian study;Multiple Sclerosis Journal;2024-08

4. Planned dose reduction of ocrelizumab in relapsing-remitting multiple sclerosis: a single-centre observational study;BMJ Neurology Open;2024-06

5. Real-world effectiveness, safety and immunogenicity of ocrelizumab in turkish multiple sclerosis patients: a single-center experience for 4-year follow-up;Acta Neurologica Belgica;2024-05-20